78 completed, 75 recruiting, 36 unknown, 28 active not recruiting. 94 Phase 2, 67 Phase 1, 50 Not applicable, 50 Phase 3, 8 Phase 4.
Follow Non-Muscle Invasive Bladder Neoplasms: new trials by email Literature Review of Non-Muscle Invasive Bladder Neoplasms trials Research Report on Non-Muscle Invasive Bladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. Hyperthermic intravesical chemotherapy (HIVEC) - Non-muscle Invasive Bladder Cancer (NMIBC) | Not applicable | Not yet recruiting | Eight Medical International BV | 30 | 2027-01-01 | 2026-08-14 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer TTP-ICG NIR fluorescent diagnostic agent - NMIBC | Phase 1 / Phase 2 | Not yet recruiting | Yunnan Cancer Hospital | 30 | 2026-10-30 | 2026-09-24 |
| Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients Hyperthermic Intravesical Chemotherapy (HIVEC) - Non Muscle Invasive Bladder Cancer, Bladder Cancer | Not applicable | Not yet recruiting | AC.TA. S.r.l. | 50 | 2026-10-15 | 2026-05-06 |
| The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer Definitive radiotherapy, BCG, Concurrent chemotherapy - Non Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Assiut University | 70 | 2026-10-02 | 2026-10-14 |
| Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors ATLAS system - NMIBC | Not applicable | Recruiting | Optheras AS | 25 | 2026-10-02 | 2026-10-06 |
| Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT Toripalimab (JS001 ), Gemcitabine (GEM) - Non Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 54 | 2026-10-01 | 2026-09-08 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 1 | Recruiting | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 30 | 2026-09-28 | 2026-10-13 |
| A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Hamlet Pharma AB | 194 | 2026-09-17 | 2026-09-21 |
| A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC). RAG-01, Chemotherapy agent - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | Ractigen Therapeutics. | 114 | 2026-09-01 | 2026-09-15 |
| Feasibility of HISA During TURBT for NMIBC HISA - Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Not applicable | Not yet recruiting | CAMC Health System | 40 | 2026-08-15 | 2026-09-14 |
| Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC Active Surveillance, Adjuvant Intravesical Chemotherapy - Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC) | Not applicable | Recruiting | Tianjin Medical University Second Hospital | 670 | 2026-08-10 | 2026-10-09 |
| Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application Supportive care program, Implementing routine urology outpatient infusion nursing - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Not applicable | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 40 | 2026-08-01 | 2026-08-24 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) Non-Muscle Invasive Bladder Cancer, NMIBC | Recruiting | Natera, Inc. | 400 | 2026-07-27 | 2026-08-13 | |
| Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study Radiation therapy - Non-Muscle Invasive Bladder Cancer | Not applicable | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2026-07-23 | 2026-09-11 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
Showing 20 of 282. Sign in to see all of them.
Urinary Bladder Neoplasms (146) · Carcinoma, Transitional Cell (26) · Neoplasms (23) · Recurrence (22) · Carcinoma in Situ (18) · Urologic Neoplasms (15) · Urinary Bladder Diseases (11) · Disease Progression (10) · Urologic Diseases (9) · Urogenital Neoplasms (7) · Neoplasms by Site (5) · Carcinoma (3) · Disease (3) · Neoplasm Metastasis (3)
Female Urogenital Diseases (282) · Female Urogenital Diseases and Pregnancy Complications (282) · Male Urogenital Diseases (282) · Neoplasms by Histologic Type (282) · Urogenital Diseases (282) · Neoplasms, Glandular and Epithelial (281) · Carcinoma (279) · Neoplasms by Site (277) · Urogenital Neoplasms (275) · Urologic Diseases (273) · Urinary Bladder Diseases (271) · Urologic Neoplasms (267) · Neoplasms (259) · Urinary Bladder Neoplasms (136) · Pathological Conditions, Signs and Symptoms (36)
Gemcitabine (33) · Mitomycin (27) · BCG Vaccine (13) · Docetaxel (11) · Epirubicin (7) · Cystoscopy (6) · Radiotherapy (5) · dodecyl maltoside (5) · durvalumab (5) · erdafitinib (5) · ALT-803 (4) · apaziquone (4) · 5-aminolevulinic acid hexyl ester (3) · disitamab vedotin (3) · pembrolizumab (3)
UroGen Pharma Ltd. (11) · Mansoura University (10) · ImmunityBio, Inc. (7) · Janssen Research & Development, LLC (7) · CG Oncology, Inc. (4) · Memorial Sloan Kettering Cancer Center (4) · Pfizer (4) · Protara Therapeutics (4) · University of Rome Tor Vergata (4) · AstraZeneca (3) · Eli Lilly and Company (3) · Endo USA Inc., a Keenova Therapeutics Company (3) · Fudan University (3) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (3) · Jørgen Bjerggaard Jensen (3)
United States (111) · China (44) · Italy (28) · Spain (25) · Canada (24) · France (24) · United Kingdom (20) · Germany (17) · Egypt (16) · Israel (16) · Australia (14) · South Korea (14) · Poland (12) · Belgium (11) · Japan (11)
Ahmed Mosbah, MD (4) · Eugene Pietzak, MD (4) · Savino M Di Stasi, MD, PhD (3) · Sebastian Mirkin, MD (3) · Ahmed A. Shokeir (2) · Ahmed Elkashef (2) · Ahmed Mosbah (2) · Ali Kaan Yildiz (2) · Bobby Reddy, MD (2) · Cheryl T Lee, MD (2) · Dingwei Ye (2)
PMID 34125951, PMID 21831711, PMID 29203268, PMID 38265030, PMID 38953850, PMID 40194933, PMID 41074972, PMID 10519404, PMID 12913696, PMID 15586136, PMID 16389183, PMID 19171491, PMID 20509796, PMID 20855414, PMID 21163569, PMID 22280855, PMID 2265339, PMID 23088985, PMID 23510863, PMID 24490762, PMID 25123116, PMID 25910967, PMID 26014293, PMID 26803476, PMID 26879805, PMID 28341495, PMID 28705539, PMID 28712033, PMID 28755959, PMID 28834453, PMID 28886381, PMID 28981385, PMID 29801011, PMID 29859728, PMID 29979488, PMID 30448030, PMID 31273010, PMID 31522458, PMID 31752752, PMID 32615118, PMID 32875619, PMID 32891506, PMID 33253641, PMID 33924556, PMID 34051177, PMID 34053856, PMID 34103518, PMID 34433303, PMID 34511303, PMID 34561265
2023 (7), 2019 (3), 2014 (2), 2016 (2), 2017 (2), 2009 (1), P30CA093373 (1), R01CA252057 (1), R01CA289268 (1), R01CA296175 (1), R37CA275916 (1), R42CA171552 (1), U10CA180820 (1), U54GM104942 (1), UL1TR002377 (1)